Bacterial infection remains as one of the major healthcare issues, despite significant
scientific and medical progress in this field. Infection by Streptococcus Pneumoniae (S …

Multivalent pneumococcal vaccines have been developed successfully to combat invasive
pneumococcal diseases (IPD) and reduce the associated healthcare burden. These …

Capsular polysaccharides (CPSs), with which most pathogenic bacterial surfaces are
decorated, have been used as the main components of glycoconjugate vaccines against …

Currently licensed pneumococcal vaccines are based on the generation of antibodies to the
pneumococcal polysaccharide, of which there are more than 90 different types. While these …

The Streptococcus pneumoniae bacteria has over 100 known serotypes that display a
continuous change in prevalence by patients' age and geographical location and therefore …

In this study, we synthesized a 5-valent pneumococcal conjugate vaccine, which was
prepared with the pneumococcal capsular polysaccharides (PCPs)(from Streptococcus …

The 13-valent pneumococcal conjugate vaccine (PCV-13) is recommended for HIV-infected
people, although its effectiveness in this population remains under evaluation. In this study …

Infections by Streptococcus pneumoniae can cause serious pneumococcal diseases and
other medical complications among patients. Polysaccharide-based vaccines have been …

S treptococcus pneumoniae‐related infections are a major cause of morbidity and mortality
in people of all ages worldwide. Pneumococcal vaccine development started in 1911 with a …

The efforts were focused on exploring alternative pneumococcal vaccine strategies, aimed
at addressing the shortcomings of existing formulations, without compromising efficacy. Our …